Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip)

Rau, Beate; Feldbrügge, Linda; Gronau, Felix; Vilchez, Miguel Enrique Alberto; Thuss-Patience, P.; Bonnot, Pierre Emmanuel; Gléhen, Olivier

doi:10.1159/000522604

Cited by 6 publications

(7 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the 1980s, there have been several randomized controlled trials (RCTs) and retrospective case-control studies investigating the use of HIPEC in patients with GCa [3]. A 2012 metanalysis based on 10 RCTs analyzed the outcomes for prophylactic HIPEC in patients with advanced GCa without distant metastasis who were randomized to undergo surgical resection alone versus surgical resection with HIPEC.…”

Section: Rationale For Hipec and Crs In Metastatic Gastric Cancermentioning

confidence: 99%

“…Gastric cancer (GCa) is the fifth most commonly diagnosed cancer in the world, but the third leading cause of cancer-related mortality worldwide [1][2][3]. In fact, only 25% of patients will survive 5 years [2,4].…”

Section: Introductionmentioning

confidence: 99%

“…The majority of patients with GCa are initially diagnosed with advanced disease, with PM present in 15-30% [3,[5][6][7]. Alarmingly, even amongst patients that appear potentially resectable with less advanced disease on pre-therapy imaging, upwards of 30% are discovered to have PM at initial staging laparoscopy.…”

Section: Introductionmentioning

confidence: 99%

“…Whilst the survival rates of patients with GCa have improved, PM in patients with GCa is associated with poor survival rates of only months [3,[22][23][24]. The dissemination of free tumor cells through blood or lymph in the abdominal cavity is considered one of the most common causes of PM in GCa, thus it is imperative that physicians find ways to eliminate free tumor cells in the abdominal cavity [25].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Jain,

Badgwell

2023

JCM

View full text Add to dashboard Cite

Gastric cancer (GCa) is an aggressive malignancy, representing the third leading cause of cancer mortality worldwide. The poor prognosis of GCa can be associated with the prevalence of peritoneal metastasis (PM). Current international and national GCa treatment guidelines only recommend palliative treatment options for patients with PM. Since the 1980s there have been multiple single arm trials, randomized controlled trials, and metanalysis investigating the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced GCa, with or without PM. Results from these studies have been encouraging, with some large-volume centers even incorporating HIPEC into their treatment algorithms for patients with advanced GCa. Additionally, there are several ongoing trials that, when completed, will increase our understanding of the efficacy of CRS & HIPEC in patients with GCa metastatic to the peritoneum. Herein we review the current evidence, ongoing trials, consensus guidelines, and future considerations regarding the use of CRS & HIPEC in patients suffering from GCa with PM.

show abstract

Section: Rationale For Hipec and Crs In Metastatic Gastric Cancermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Jain,

Badgwell

2023

JCM

View full text Add to dashboard Cite

show abstract

“…Another surgical approach that has no clear benefit in terms of survival in AGC patients is Hyperthermic Intraperitoneal Chemotherapy (HIPEC) combined with surgery in patients with peritoneal metastasis only. [79][80][81]…”

Section: Surgerymentioning

confidence: 99%

Optimizing the Continuum of Care in Gastric Cancer

Riccò,

Martinelli,

Bardasi

et al. 2023

OTT

View full text Add to dashboard Cite

Gastric cancer (GC) still ranks as the fifth most common malignancy and the fourth leading cause of cancer-related death worldwide. Despite the recent progress in the therapeutic algorithm of the advanced disease with the advent of immune checkpoint inhibitors (ICIs) and next-generation HER2-directed therapies, survival rates remain poor, with a median survival hardly exceeding 12 months. Furthermore, only 40% of patients remain eligible for second-and later-line treatments due to the aggressiveness of the disease and the rapid deterioration of performance status (PS). Thus, current research is focusing either on the identification of novel treatment options or the development of personalized strategies to optimize the continuum of care and ultimately improve patients' outcome. In this article, we provide an overview of the current treatment landscape for advanced GC with a particular emphasis on later-line treatments and outline novel perspectives on the horizon.

show abstract

Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Zhou,

Cai,

et al. 2024

J Gastrointest Canc

View full text Add to dashboard Cite

To evaluate the short-term safety of albumin-bound paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) during and after gastric cancer (GC) surgery. MethodsA retrospective analysis of clinical data was conducted for GC surgery patients at Zhongnan Hospital of Wuhan University, from January 2020 to September 2022. The study group (n = 120) received HIPEC and the control group (n = 268) did not receive albumin-bound paclitaxel. Short-term safety indicators including intraoperative complications, hematological toxicity, liver and kidney function, and gastrointestinal function recovery, were compared between the two groups. ResultsThere were no statistically signi cant differences between the two groups regarding intraoperative complications, hematological toxicity, liver and kidney function, and gastrointestinal function recovery time (P > 0.05 for all). In the study group, patients were further divided into subgroups based on dose and timing. Subgroup analysis revealed no signi cant differences among the different dose subgroups.However, when focusing on timing subgroups, postoperative subgroup exhibited signi cantly higher white blood cell counts and bilirubin levels compared to intraoperative subgroup, while the intraoperative subgroup had signi cantly higher bilirubin levels compared to both postoperative and intraoperative plus postoperative subgroups. ConclusionAlbumin-bound paclitaxel demonstrates good safety and tolerability in HIPEC during and after GC surgery, without increasing the risk of intraoperative complications.This study aims to comprehensively assess the short-term safety of albumin-bound paclitaxel in GC patients receiving HIPEC, and the results are reported as follows. MATERIALS AND METHODS PatientsA retrospective analysis of clinical data was conducted for 388 gastric cancer (GC) patients treated in the

show abstract

Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip)

Cited by 6 publications

References 81 publications

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Current Evidence for the Use of HIPEC and Cytoreductive Surgery in Gastric Cancer Metastatic to the Peritoneum

Optimizing the Continuum of Care in Gastric Cancer

Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Contact Info

Product

Resources

About